We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Nutriband Inc (NTRB) USD0.001

Sell:$3.49 Buy:$3.94 Change: $0.39 (9.92%)
Market closed |  Prices as at close on 22 April 2024 | Switch to live prices |
Sell:$3.49
Buy:$3.94
Change: $0.39 (9.92%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 April 2024 | Switch to live prices |
Sell:$3.49
Buy:$3.94
Change: $0.39 (9.92%)
Market closed |  Prices as at close on 22 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. The Company's development pipeline includes AVERSA Buprenorphine and AVERSA Methylphenidate. The Company is also developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. Its AVERSA Fentanyl is an abuse-deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse-deterrent technology to reduce the abuse and misuse of fentanyl patches. It is also exploring transdermal delivery of proteins and peptides such as exenatide for type 2 diabetes and follicle-stimulating hormone (FSH) for infertility.

Contact details

Address:
121 S Orange Ave Ste 1500
ORLANDO
32801-3241
United States
Telephone:
+1 (407) 3776695
Website:
https://nutriband.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NTRB
ISIN:
US67092M2089
Market cap:
$30.78 million
Shares in issue:
7.83 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Serguei Melnik
    Chairman of the Board, President, Secretary
  • Gareth Sheridan
    Chief Executive Officer, Founder, Director
  • Gerald Goodman
    Chief Financial Officer, Chief Accounting Officer
  • Alan Smith
    Chief Operating Officer, President of 4P Therapeutics
  • Patrick Ryan
    Chief Technical Officer
  • Jeff Patrick
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.